Stockreport

MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

MacroGenics, Inc.  (MGNX) 
Last macrogenics, inc. earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.macrogenics.com
PDF ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing inn [Read more]